Latest From Ardana PLC
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
The UK firm Atlantic Healthcare has promoted its chief commercial officer, Dr Huw Jones, to CEO of its therapeutics division, Atlantic Pharmaceuticals.
The marine biotechnology company Aquapharm Biodiscovery (UK) has appointed Dr Tim Morley chief scientific officer. He has more than 20 years' experience in the pharmaceutical industry, having previously served as research and strategic project director at Quotient Biodiagnostics, vice-president of preclinical sciences at Ardana Bioscience and senior director molecular and cellular pharmacology at Vernalis.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Ardana Bioscience Ltd.
- Western Europe
- Parent & Subsidiaries
- Ardana PLC
- Senior Management
Graham Lee, CFO
Finn Larsen, MD, VP, Clinical Dev.
Karen Gardiner, PhD, Dir., Bus. Dev.
- Contact Info
Phone: (44) 131 2268550
38 Melville St.
Edinburgh, EH3 7HA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.